Evidence map›Paper›PMID 27231035›Full record

ArticleAIDS research and human retroviruses

Glycosylphosphatidylinositol Anchor Deficiency Attenuates the Production of Infectious HIV-1 and Renders Virions Sensitive to Complement Attack.

Tohti Amet, Jie Lan, Nicole Shepherd, Kai Yang, Daniel Byrd, Yanyan Xing, Qigui Yu

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. [Advances in application of Jurkat cell model in research on infectious diseases].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Tohti Amet1 Department of Microbiology and Immunology, Indiana Center for AIDS Research, Indiana University School of Medicine , Indianapolis, Indiana.
Jie Lan1 Department of Microbiology and Immunology, Indiana Center for AIDS Research, Indiana University School of Medicine , Indianapolis, Indiana.
Nicole Shepherd1 Department of Microbiology and Immunology, Indiana Center for AIDS Research, Indiana University School of Medicine , Indianapolis, Indiana.
Kai Yang2 Wenzhou Institute of Biomaterials and Engineering , Wenzhou, China .
Daniel Byrd1 Department of Microbiology and Immunology, Indiana Center for AIDS Research, Indiana University School of Medicine , Indianapolis, Indiana.
Yanyan Xing1 Department of Microbiology and Immunology, Indiana Center for AIDS Research, Indiana University School of Medicine , Indianapolis, Indiana.
Qigui Yu1 Department of Microbiology and Immunology, Indiana Center for AIDS Research, Indiana University School of Medicine , Indianapolis, Indiana.
Indiana University – Purdue University Indianapolis · USJinan University · CNWenzhou Institute of Industrial Science · CN

Funding

Immunology and Infectious Diseases Training ProgramT32AI060519 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI MARK H KAPLAN · 2004 to 2026
$6.0M
Targeting latently infected Tfh cells to achieving a functional cure of HIV-1R01AI117835 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI YU, QIGUI A. · 2015 to 2019
$1.9M
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR015481 · NCRR · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI FIFE, ROSE S · 2001 to 2001
$1.6M
Specific killing of latently HIV-1-infected cells after provirus reactivationR33AI104268 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI YU, QIGUI A. · 2015 to 2017
$1.2M
NCRR NIH HHS C06 RR015481NIAID NIH HHS R01 AI117835NIAID NIH HHS R33 AI104268NIAID NIH HHS T32 AI060519
6 · The paper itself

Abstract

Human immunodeficiency virus type 1 (HIV-1) escapes complement-mediated lysis (CML) by incorporating host regulators of complement activation (RCA) into its envelope. CD59, a key member of RCA, is incorporated into HIV-1 virions at levels that protect against CML. Since CD59 is a glycosylphosphatidylinositol-anchored protein (GPI-AP), we used GPI anchor-deficient Jurkat cells (Jurkat-7) that express intracellular CD59, but not surface CD59, to study the molecular mechanisms underlying CD59 incorporation into HIV-1 virions and the role of host proteins in virus replication. Compared to Jurkat cells, Jurkat-7 cells were less supportive to HIV-1 replication and more sensitive to CML. Jurkat-7 cells exhibited similar capacities of HIV-1 binding and entry to Jurkat cells, but were less supportive to viral RNA and DNA biosynthesis as infected Jurkat-7 cells produced reduced amounts of HIV-1 RNA and DNA. HIV-1 virions produced from Jurkat-7 cells were CD59 negative, suggesting that viral particles acquire CD59, and probably other host proteins, from the cell membrane rather than intracellular compartments. As a result, CD59-negative virions were sensitive to CML. Strikingly, these virions exhibited reduced activity of virus binding and were less infectious, implicating that GPI-APs may be also important in ensuring the integrity of HIV-1 particles. Transient expression of the PIG-A gene restored CD59 expression on the surface of Jurkat-7 cells. After HIV-1 infection, the restored CD59 was colocalized with viral envelope glycoprotein gp120/gp41 within lipid rafts, which is identical to that on infected Jurkat cells. Thus, HIV-1 virions acquire RCA from the cell surface, likely lipid rafts, to escape CML and ensure viral infectivity.

Indexed as

Virus AssemblyCD59 AntigensComplement System ProteinsGlycosylphosphatidylinositolsHIV-1Host-Pathogen InteractionsHumansJurkat CellsVirionCD59 AntigensCD59 protein, humanComplement System ProteinsGlycosylphosphatidylinositolsantibodycomplementGPI-APHIV-1virus bindingvirus replication

Identifiers

PMID27231035
PMCPMC5067833
OpenAlexW2515307392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.